Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Open evidence library

Search the archive.

Current and older evidence is free during beta. Sign in for unlimited card access and full source downloads.

Matching cards
2022 Michigan Disadvantage
PTX Updates › Midterms

Healthcare bill passage before midterms boosts dem popularity

Margot Sanger-Katz 22, 7-15-2022, "Build Back Better Is a Health Care Bill Now," No Publication, https://www.nytimes.com/2022/07/15/upshot/build-back-better-health-care-biden.html

WASHINGTON — President Biden and Democrats in Congress had hoped to pass a broad domestic policy package that would expand the social safety net, raise taxes on corporations and the wealthiest Americans, and tighten regulation of climate-changing pollutants. But the decision by Senator Joe Manchin of West Virginia to withdraw his support from other aspects of an already-shrunken package this week leaves nothing but health care on the table. But even if what was once a sidecar of sorts to the so-called Build Back Better Act is now the only vehicle left on the road, it would still have a substantial impact on the lives of many Americans. And unlike other provisions that faced a mixed political reception, the central health care proposal that remains is enormously popular with the public — including Republicans. That piece is prescription drug price reform, which Democrats have been promising for years and many Americans tell pollsters they want. The bill would take several whacks at the price of drugs — directly regulating prices for a group of expensive medications purchased by Medicare and punishing drug companies that raise prices too fast on existing medicines for all Americans. The legislation under discussion would also expand Medicare’s prescription drug benefit, increasing financial help for poorer seniors and eliminating the program’s current unlimited cost sharing, which leaves some beneficiaries facing more than $10,000 a year in medication costs. No one on Medicare would be asked to pay more than $2,000 a year for prescription drugs under the legislation, a significant benefit to patients who take expensive medications for serious diseases like cancer and multiple sclerosis. The prescription drug provisions are unusual in that they offer Americans tangible benefits — lower drug prices, more financial protections — while actually saving the federal government money. That’s because the bill essentially puts the savings on the back of the pharmaceutical industry, which will have to accept lower prices for some of its big sellers. Understand What Happened to Biden’s Domestic Agenda Card 1 of 6 ‘Build Back Better.’ Before being elected president in 2020, Joseph R. Biden Jr. articulated his ambitious vision for his administration under the slogan “Build Back Better,” promising to invest in clean energy and to ensure that procurement spending went toward American-made products. A two-part agenda. March and April 2021: President Biden unveiled two plans that together formed the core of his domestic agenda: the American Jobs Plan, focused on infrastructure, and the American Families Plan, which included a variety of social policy initiatives. A $6 trillion budget. June 2021: President Biden proposed a $6 trillion budget for 2022. The proposal detailed the highest sustained levels of federal spending since World War II, with the goal of funding the investments in education, transportation and climate initiatives articulated in the two plans. The Infrastructure Investment and Jobs Act. Nov. 15, 2021: President Biden signed a $1 trillion infrastructure bill into law, the result of months of negotiations. The president hailed the package, a pared-back version of what had been outlined in the American Jobs Plan, as evidence that U.S. lawmakers could still work across party lines. The Build Back Better Act. Nov.19, 2021: The House narrowly passed a $2.2 trillion social spending bill intended to fund a package of initiatives from the American Families Plan and the American Jobs Plan. But on Dec. 19, 2021, Senator Joe Manchin III, Democrat of West Virginia, said he would not support the bill as written, dooming his party’s drive to pass it. A new attempt. July 15, 2022: Efforts to revive the bill, in a much smaller form, ahead of the midterm elections were dealt a severe blow when Mr. Manchin told Senator Chuck Schumer, the majority leader, that he was unwilling to support funding for climate or energy programs or raising taxes on wealthy Americans and corporations. Defenders of the industry in Congress, and the drug companies themselves, argue that the change could thwart innovation and cost jobs. Such arguments have staved off drug price reforms in the past. But previous rounds of negotiation suggest that this package is likely to have enough votes to pass the Senate. Dig deeper into the moment. Special offer: Subscribe for $1 a week. Mr. Manchin has also signaled his support for another health provision that has received less attention in recent reports of the emerging deal. He said he was open to an expansion of premium subsidies that lower the price of insurance for Americans who buy their own coverage, rather than get it through the government or a job. Those subsidies were already expanded as part of Congress’s pandemic relief bill last year, but the expansion will expire in December unless new legislation continues them. The subsidies are important to many Democratic lawmakers because they are seen as fulfilling the promise of the Affordable Care Act. The extra money lowers premiums for nearly every American who buys a health plan through the Obamacare marketplaces, making certain plans free for lower-income Americans and offering financial support for higher-income people who previously received no help paying for insurance. In a statement on Friday supporting the measures in which he called on the Senate to pass the legislation before its August recess, Mr. Biden said Democrats had “come together” and “beaten back the pharmaceutical industry.” “This will not only lower the cost of prescription drugs and health care for families,” he added, “it will reduce the deficit and help fight inflation.” But for Democrats who had hoped for social spending on programs other than health care, the price of extending the Obamacare subsidies may disappoint. A slightly outdated estimate suggests they will cost the federal government nearly as much to extend as the drug-pricing provisions would save — $220 billion over a decade, compared with about $288 billion in savings. Mr. Manchin has said he might be open to considering climate and tax provisions in the fall. If he is also hoping for deficit reduction, there may be less money to spend than some lawmakers expected.

2022 Michigan Disadvantage
PTX Updates › BBB-- AHA! its still alive

Their evidence exaggerates Manchins claim—he just didn’t want to pass the bill in July

Jacob Fischler 22, 7-15-2022, "Climate change legislation still could pass Congress this year, Manchin insists," Iowa Capital Dispatch, https://iowacapitaldispatch.com/2022/07/15/climate-change-legislation-still-could-pass-congress-this-year-manchin-insists/

U.S. Sen. Joe Manchin III on Friday held open the prospect of Congress passing significant climate legislation yet this year, denying reports he’s tanked the effort by walking away from talks with leadership. The reports have brought a flood of criticism for Manchin from fellow members of Congress, who say the very survival of the planet is at stake. Manchin, a moderate West Virginia Democrat, gains unusual national attention for his remarks because he is in the center of his party’s negotiations over a major spending bill and represents a crucial vote in the evenly divided Senate. Manchin on a West Virginia radio station talk show on Friday said he told Senate Majority Leader Chuck Schumer that after June’s consumer price index showed a 9.1% increase, he wanted to wait to see July’s inflation numbers and Federal Reserve interest rates before deciding what clean energy programs and tax changes he could support. “Let’s wait until that comes out so that we know that we’re going down the path that won’t be inflammatory to add more to inflation,” Manchin said he told Schumer, a New York Democrat. “Inflation is absolutely killing many, many people… Can’t we wait to make sure that we do nothing to add to that?” Schumer “took that as ‘no,’ I guess, and came out with this big thing last night,” Manchin told Hoppy Kercheval, the host of the Metronews Talkline radio show in West Virginia. The New York Democrat or someone close to him then told The Washington Post that talks were dead, Manchin implied. The Post published a story Thursday night saying Manchin told Democratic leaders he wouldn’t support new climate programs or raising taxes on the wealthy. Manchin seemed surprised by the Washington Post report, saying during a 15-minute interview with Kercheval that Schumer’s team knew where the West Virginian stood and that the sides had made major progress in the past few months. He seemed to view the leak as a negotiating ploy, rejecting the conclusion that talks were at an end or even seriously set back. “I’m not stopping,” he said. “This is rhetoric. I’ve been through this all my life, politically. I’ve never seen it at this level… thinking they’re going to put all this pressure on me. I am where I have been. I would not put my staff through this, I would not put myself through this if I wasn’t sincere.” Reconciliation bill Manchin said Schumer wanted an agreement by the end of July on a budget reconciliation bill — a legislative tool that would allow Senate Democrats to pass legislation with a simple majority vote, which they’d gain with Vice President Kamala Harris breaking a tie. Inflation figures for July will not be released until August, when the Senate will be in a month-long recess. Manchin has also set a Sept. 30 deadline to reach a deal on a spending bill, making the four weeks the chamber is in session in September a crucial period. That tight timeline was not an obstacle, he said Friday. “We could come back the first of September and pass this legislation,” he said. “If it’s a good piece of legislation.” Manchin said he thought he was “close” to a deal with Schumer. “I thought we were,” he said. “I thought we were moving truly in the right direction.” Energy policy differences Manchin, who has financial ties to his state’s coal industry, said he supports spending for clean energy programs, but had disagreements with Democratic colleagues who he said wanted to eliminate production of oil, gas and coal. That may happen in 20 years, but would not be possible in the next decade, Manchin said. The U.S. should instead work on making fossil fuel production cleaner and on developing non-fossil fuel sources, including hydrogen and nuclear, he said. Carbon emissions from fossil fuels are the dominant cause of global warming, according to the Intergovernmental Panel on Climate Change. The international group has called for significant reductions to fossil fuel emissions in order to curb the worst effects of climate change. President Joe Biden has joined international efforts to reduce carbon emissions, including cutting greenhouse gas emissions to 50% of 2005 levels by 2030. The White House proposed — and the Democratic-controlled House passed last year — more than $550 billion for climate programs, mostly tax credits for energy producers that use renewable sources. Manchin’s objections sidelined that bill in December. Manchin ‘whims’ criticized Climate advocates in and out of Congress slammed Manchin on Friday, reacting to apparent news he had again blocked even a slimmed-down climate bill. “Like most Americans right now, I am sickened that the changing whims of one man could put the very near future of our country, our planet, and our health and safety on the brink,” U.S. House Natural Resources Committee Chairman Raúl M. Grijalva of Arizona said in a statement. “I think it’s shortsighted at best, reckless endangerment at worst.” Grijalva also blamed Republicans for the impasse. “It’s infuriating and nothing short of tragic that Senator Manchin is walking away, again, from taking essential action on climate and clean energy,” Minnesota Democratic Sen. Tina Smith said in a statement. “The world is literally burning while he joins every single Republican to stop strong action to cut emissions and speed the transition to clean energy for the survival of our planet.” “We have an opportunity to address the climate crisis right now,” U.S. Sen. Martin Heinrich of New Mexico, who sits on the Energy and Natural Resources Committee that Manchin chairs, wrote on Twitter. “Senator Manchin’s refusal to act is infuriating,” Heinrich added. “It makes me question why he’s Chair of ENR.” “This failure falls squarely on Joe Manchin and the Republicans, as do the barren croplands, flooded homes, and incinerated communities that will result from this inaction,” said Manish Bapna, the president and CEO of environmental group NRDC Action Fund. “One of those senators must reconsider.” Representatives for Schumer, who has been absent from the Senate with COVID-19, did not respond to a message seeking comment Friday.

2022 Michigan Disadvantage
PTX Updates › BBB-- AHA! its still alive

Manchin walked back and is open to climate negotiations later – only by walking on egg shells can the bill be passed in September – floor time and PC are key

Emily Cochrane 22, 7-15-2022, "Manchin Dangles Hopes of a Future Compromise. Democrats Revolt.," https://www.nytimes.com/2022/07/15/us/politics/joe-manchin-senate-climate-tax.html?auth=login-google

WASHINGTON — It was a familiar, if excruciating, position for Democrats. A day after pulling the plug on his party’s plans to pass a climate, energy and tax package this summer, Senator Joe Manchin III of West Virginia, the conservative-leaning Democrat who has repeatedly flirted with compromise only to scuttle his party’s highest ambitions, called in on Friday to a West Virginia radio show. Perhaps, he suggested, in another month or so, he might see his way clear to salvaging the last bits of President Biden’s domestic agenda. There was no guarantee, of course, and the comments were only the latest instance of Mr. Manchin capitalizing on his role as a swing vote in an evenly divided Senate to dictate his party’s legislative strategy, leaving Democrats at his mercy. This time, Democrats had had enough. Rather than engage in another round of will-he-or-won’t-he negotiations with Mr. Manchin, Mr. Biden let it be known that he was done trying to secure his climate agenda in Congress. Mr. Manchin’s abrupt withdrawal left Senator Chuck Schumer, Democrat of New York and the majority leader, jilted after months of courting a colleague whose demands and red lines seemed to shift by the day, or the latest economic projection. And it prodded many Democrats into open revolt against Mr. Manchin, blaming him for the demise of their ambitions and the last chance for their party to tackle the existential threat of climate change. Mr. Manchin, said Representative Pramila Jayapal of Washington, the chairwoman of the Congressional Progressive Caucus, “has shown that he doesn’t know how to close a deal — or he doesn’t want to close a deal — and that you can’t trust him.” For more than a year, Mr. Manchin, who at 74 is serving his third term in the Senate, has been situated exactly where he prefers to be: at the center of a high-stakes political and policy negotiation, with attention and speculation focused on him. Democrats have toiled to win his vote on any piece of their once-ambitious domestic agenda, tailoring their policy moves so as not to alienate him. They have contorted themselves to suit his often-changing dictates and have scaled back their ambitions repeatedly to stay within his red lines, but they have so far come away empty-handed on their biggest priorities. Because of Democrats’ razor-thin margin of control in the 50-50 Senate and unified Republican opposition to most of their agenda, Mr. Manchin has effective veto power over the party’s legislative strategy — and has exercised it often and unapologetically. But while Mr. Biden and congressional Democrats have pushed for transformative policies to confront generational challenges such as climate change, Mr. Manchin, who channels the desires of his very conservative, coal-and-gas-producing state, has focused on nearer-term issues. On Friday, he said he had told party leaders he wanted to wait another month — until inflation numbers for July were released — before he could decide on whether to act on climate change. ‘Build Back Better.’ Before being elected president in 2020, Joseph R. Biden Jr. articulated his ambitious vision for his administration under the slogan “Build Back Better,” promising to invest in clean energy and to ensure that procurement spending went toward American-made products. A two-part agenda. March and April 2021: President Biden unveiled two plans that together formed the core of his domestic agenda: the American Jobs Plan, focused on infrastructure, and the American Families Plan, which included a variety of social policy initiatives. A $6 trillion budget. June 2021: President Biden proposed a $6 trillion budget for 2022. The proposal detailed the highest sustained levels of federal spending since World War II, with the goal of funding the investments in education, transportation and climate initiatives articulated in the two plans. The Infrastructure Investment and Jobs Act. Nov. 15, 2021: President Biden signed a $1 trillion infrastructure bill into law, the result of months of negotiations. The president hailed the package, a pared-back version of what had been outlined in the American Jobs Plan, as evidence that U.S. lawmakers could still work across party lines. The Build Back Better Act. Nov. 19, 2021: The House narrowly passed a $2.2 trillion social spending bill intended to fund a package of initiatives from the American Families Plan and the American Jobs Plan. But on Dec. 19, 2021, Senator Joe Manchin III, Democrat of West Virginia, said he would not support the bill as written, dooming his party’s drive to pass it. A new attempt. July 15, 2022: Efforts to revive the bill, in a much smaller form, ahead of the midterm elections were dealt a severe blow when Mr. Manchin told Senator Chuck Schumer, the majority leader, that he was unwilling to support funding for climate or energy programs or raising taxes on wealthy Americans and corporations. “I am where I have been — I would not put my staff through this, I would not put myself through this if I wasn’t sincere about trying to find a pathway forward to do something that’s good for our country,” Mr. Manchin said on Friday in the interview with the radio host Hoppy Kercheval. “They cannot come to grips because I have a ‘D’ by my name or someone has an ‘R’ by their name, we should do whatever one side wants. That’s not me.” Mr. Biden made no mention of Mr. Manchin in a statement issued on Friday. Asked at a news conference in Jeddah, Saudi Arabia, whether the West Virginian had been negotiating in good faith, the president demurred, saying he was not the one who had been negotiating with him. But angry congressional Democrats pinned their frustration on the West Virginia Democrat. One, Senator Martin Heinrich of New Mexico, mused publicly about whether Mr. Manchin deserved his chairmanship of the Committee on Energy and Natural Resources. “It’s been a really, really terrible day,” Senator Tina Smith, Democrat of Minnesota and a key champion of the climate provisions, said in an interview. “If Senator Manchin wants a deal on climate and energy, he can have one in a heartbeat. This is Senator Manchin’s deal for the taking, and if it doesn’t happen, it is on him.” On Capitol Hill, Mr. Manchin is something of a unicorn — the only national Democrat from his ruby-red state — and acts and votes accordingly. Set to face voters in 2024, he is unlikely to be threatened by a primary challenger in a state former President Donald J. Trump won by nearly 40 points in 2020. That has given Mr. Manchin leverage to accomplish his own policy goals — including holding firm against moving entirely away from oil and gas — and resist what he considers his party’s lurch toward its liberal base. He appears happiest when he is in the middle of a consequential policy negotiation; he has been wined and dined as a crucial participant in bipartisan talks, invited to Mr. Biden’s Wilmington home for breakfast and pursued by the White House officials, lawmakers, aides and reporters who dissect his every syllable for a kernel of insight. But the murkiness, and at times inconsistency, of Mr. Manchin’s positions has increasingly grated on his Democratic colleagues. Barely three months into the Biden administration, he prompted the longest open vote in modern Senate history by raising a last-minute objection to the size of unemployment benefits in the $1.9 trillion pandemic aid plan. Democrats had to slash the jobless payments to win his vote, which cemented passage of the package. He refused to help Democrats change filibuster rules to enact voting rights legislation, killing the effort even after Mr. Schumer gave him the lead role in writing an alternative bill to ensure he would support it. But on no issue has Mr. Manchin bedeviled Democrats more than on their ambitious social safety net, climate and tax package. To win his vote to begin work on the plan, Mr. Schumer signed on to a secret memo with Mr. Manchin that made clear that the West Virginian had no intention of accepting the $3.5 trillion in spending envisioned in Democrats’ budget. The document outlined Mr. Manchin’s much narrower parameters for a $1.5 trillion package, including income thresholds for social programs and accommodations for fossil fuel tax credits and natural gas. “I will try to dissuade Joe on many of these,” Mr. Schumer scrawled on the document, which enraged many Democrats when it became public. He never could. Six months later, Mr. Manchin abruptly walked away from talks on the package. Democrats regrouped in January and began efforts to rebuild their shattered plan, adhering strictly to the components Mr. Manchin had repeatedly laid out: paying down the national debt, overhauling parts of the tax code and lowering the cost of prescription drugs by allowing Medicare to negotiate prices and some spending. By early this month, Senate Democrats had begun rolling out pieces of a package they believed could win Mr. Manchin’s support, including a drug pricing proposal and a plan to shore up the solvency of a key Medicare program by increasing taxes for some high-earning Americans. But by Thursday evening, after news that prices had surged 9.1 percent in the year ending in June, Mr. Manchin balked again, telling Mr. Schumer that he wanted to wait on any climate or tax proposals until seeing inflation figures for July. Should Democrats insist on pushing forward with legislative action before then, Mr. Manchin said, they should act only on proposals aimed at lowering the cost of prescription drugs and extending expanded Affordable Care Act subsidies. “Let’s wait until that comes out, so we know that we’re going down the path it won’t be inflammatory, to add more to inflation,” Mr. Manchin said in the radio interview. Recounting Mr. Schumer’s response, Mr. Manchin added: “I said, ‘Chuck, it’s wrong. It’s not prudent to do the other right now.’” “I want climate. I want an energy policy,” he said, adding, “I thought we were moving truly in the right direction.” But Mr. Schumer appeared to have grown exasperated and convinced that Mr. Manchin’s vote was not obtainable. One official said that Mr. Manchin had rebuffed major concessions that would have enraged progressive Democrats, including adding more drilling measures, removing a key electric vehicle tax credit and dropping tax increases he had resisted. Mr. Manchin’s stance effectively scuttled the chances of action in the coming days on a critical priority for Democrats and strongly suggested that unless they abandoned the climate and tax proposals altogether, they might not salvage any of their domestic policy package before the midterm congressional elections in November. In September, after a five-week planned recess, lawmakers will have only a limited window to act on the package. And they are eager to give themselves as much time as possible to campaign on whatever they pass before the November elections. Bearing political scars from a year of fractious talks, few Democrats on Friday seemed willing to gamble that there was a larger deal to be had in September. “I can’t get blood from a stone,” said Representative Elissa Slotkin, a Michigan Democrat facing re-election in a competitive district. “I’m not in the Senate. They’re clearly having problems negotiating among themselves. And I will just — for my constituents — take what I can get.”

2022 Michigan Disadvantage
PTX Updates › BBB -- Dead as a door knob

BBB is dead—Manchin watered it down to a Medicare bill that doesn’t solve the DA’s impacts

David Dayen 22, 7-15-2022, "May Build Back Better Never Be Spoken Of Again," American Prospect, https://prospect.org/blogs-and-newsletters/tap/may-build-back-better-never-be-spoken-of-again/

In the end, having to negotiate with a coal baron on transitioning away from fossil fuels was not the most reliable option. As you and the rest of the world know by now, Joe Manchin walked away from adding climate measures or tax increases to any party-line reconciliation package. What was once a transformative, multitrillion-dollar agenda to face numerous long-standing crises in domestic policy has narrowed to an exceptionally narrow drug price reform, the main part of which—price negotiation in Medicare—doesn’t kick in until 2026, two years after the next presidential election, and a two-year extension on ACA subsidies that were set to expire at the end of the year. Eighteen months of fruitless negotiation has come down to that. There’s going to be a ton to say about this in the coming days, and we’re certainly going to say it. We’re going to note that progressives who said that the social-spending and infrastructure plans had to be tied together or else the social spending wouldn’t happen were proven entirely correct. We’re going to reinforce that Manchin was never a viable partner in this enterprise, something that we’ve known for at least this entire year. We’re going to note that the Trump tax cuts—opposed unanimously by every Democrat in or out of Congress—are now looking incredibly likely to become permanent, without much of a fight. We’re going to try and draw lessons out of the policy and governance structures of the Democratic Party that led to this utter failure. We’re going to once again highlight, as we have for three years, the importance of executive action as the main path forward for progress in Washington. (The states are a different matter, and we’ll talk about that, too.) But first things first. Staring us in the face is this health policy bill that by all accounts has the support of all 50 Democratic senators. That should be passed the moment that those 50 senators are physically available to cast a vote in the chamber. Manchin made a play at walking back his comments on local radio today, saying that climate measures weren’t dead, that he just wants to see one more inflation report, just one more set of data, before coming back and hammering something out in September. Humoring him would be a colossal mistake. Manchin has shown the world who he is; Chuck Schumer spending one more second in a room with him would be absurd. If he wants to go down in history as the man responsible for the diminishment of life on Earth, that’s between him and his network of coal companies. What we’re left with on the table isn’t great, but it is, and this is a low bar, a lot better than nothing. The drug price reform is narrow and pinched and limited mostly to seniors and it still saves nearly $300 billion in Medicare costs, plus a lot more for individual patients. Extending the ACA subsidies prevents the self-own October surprise of a spike in insurance premiums. Yes, a two-year extension sets up the same brinkmanship and potential premium spike before the presidential election, but Republicans will share some of the blame for that if they control the House and/or Senate, and a presidential race could be a better stage for highlighting that issue. Most important, stopping the will-they-or-won’t-they is an absolute political imperative. The party is exhausted by failure, and won’t hold out for another couple months of wishes and hopes. Eighteen months of Joe Manchin being America’s most well-known Democrat is enough. Just put the bill on the floor and get this over with. Get something completed, and spend the August recess thinking about how we got here.

2022 Michigan Negative
Disad things › AT: Solvency › 1NC – No Enforcement

A lack of political will, hidden manufacturers, and industry pressure make standards unenforceable

Samore 21 -- Professor of the Politics and Middle East Studies at Brandeis University. Senior official in the National Secuirty Council for nonprolif of wmds under Clinton and Obama, MA and PhD from the Government Department of Harvard University [Gary. “Nobody is Checking for Violations of the Biological Weapons Convention.” Global Biodefense. 9/23/2021. https://globalbiodefense.com/2021/09/23/nobody-is-checking-for-violations-of-the-biological-weapons-convention/]

CDC microbiologist suited up inside a BSL-4 high containment laboratory. Credit: CDC / Dr. Scott Smith

A global treaty bans development or stockpiling of biological weapons — but allows biodefense planning.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › --xt Carbon neutrality fails

Carbon neutrality isn’t enough

Kirkpatrick 19 [David Kirkpatrick, journalist and founder of Techonomy, 11-14-2019, “Carbon Neutral Isn't Enough”, Techonomy, https://techonomy.com/carbon-neutral-isnt-enough/, 6-28-2022]

Many people believe that if we all just drove electric cars, used LED lightbulbs, and even did things like sail across the ocean rather than fly, the resulting reduction in pollution could somehow stop global warming. Unfortunately, it isn’t true. Yes, the world has to radically reduce emissions of carbon dioxide (CO2) and other global warming gasses. But to avoid planetary catastrophe, we also must remove a vast amount of CO2 that’s already in our atmosphere.

The United Nations’ Intergovernmental Panel on Climate Change (IPCC) says average global temperatures cannot be allowed to exceed, at the very most, 2 degrees centigrade above the average that prevailed before industrialization. If possible, the increase shouldn’t exceed 1.5 degrees. Otherwise, we face even more violent weather, damaging wildfires, rising sea levels, water scarcity, an unstable food supply, and who knows what other horrors. And here is a key but little-discussed passage from an important 2018 IPCC report: “All pathways that limit global warming to 1.5°C with limited or no overshoot project the use of carbon dioxide removal (CDR).” Note the word–“all.”

2022 Michigan Negative
Disad things › AT: Biotech Advantages › --xt past tipping points

We’ve already passed the climate tipping point

Carrington 22 (Damian Carrington, “Extreme heat in oceans ‘passed point of no return’ in 2014, The Guardian, February 1 2022, , WC-NAS)

Extreme heat in the world’s oceans passed the “point of no return” in 2014 and has become the new normal, according to research.

Scientists analysed sea surface temperatures over the last 150 years, which have risen because of global heating. They found that extreme temperatures occurring just 2% of the time a century ago have occurred at least 50% of the time across the global ocean since 2014.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC – AT: Climate

Biotech won’t solve climate

Lancaster University 20 [4-20-2020, “Why relying on new technology won't save the planet”, Science Daily, https://www.sciencedaily.com/releases/2020/04/200420125510.htm, 6-27-2022]

Researchers Duncan McLaren and Nils Markusson from Lancaster Environment Centre say that: "For forty years, climate action has been delayed by technological promises. Contemporary promises are equally dangerous. Our work exposes how such promises have raised expectations of more effective policy options becoming available in the future, and thereby enabled a continued politics of prevarication and inadequate action.

"Prevarication is not necessarily intentional, but such promises can feed systemic 'moral corruption', in which current elites are enabled to pursue self-serving pathways, while passing off risk onto vulnerable people in the future and in the global South.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC – AT: Climate

Biotech doesn’t solve climate/ cap link?

Fuge 21 [Lauren Fuge, a science journalist at Cosmos and holds a BSc in physics from the University of Adelaide, 8-5-2021, “ Tech alone cannot solve climate crisis”, Cosmos, https://cosmosmagazine.com/technology/tech-alone-cannot-solve-climate-crisis/, 6-27-2022]

An international team of scientists says that we cannot rely on technology to meet climate targets – instead, wealthy countries must change their lifestyles to dramatically reduce emissions and avoid climate breakdown.

The new article, published in Nature Energy, calls for the urgent development of new climate models that explore ways economies can remain stable without constantly growing, reducing the reliance on potentially unfeasible new technologies to fix our problems.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC - Soft Regulation Fails

Soft power fails

Cecire 14 [Michaeal Cecire, a Black Sea and Eurasia regional analyst and an associate scholar at the Foreign Policy Research Institute, 4-1-2014, “The Limits of Soft Power”, The National Interest, https://nationalinterest.org/commentary/the-limits-soft-power-10163, accessed 6-27-2022]

The Russian invasion of Ukraine has already punctured much of the prevailing foreign-policy thinking that had become pro forma in Washington and Europe. In particular, the notion that Western unilateral disarmament can somehow be balanced or compensated for with less tangible forms of influence—soft power—has much to answer for in this ongoing crisis. By now, it is clear that Moscow’s actions in Crimea strongly demonstrate the sharp limits of soft power, especially one that appears to have been decoupled from hard power, the traditional final arbiter of interstate relations. Ukraine is not merely a geopolitical setback, but a symptom of a misplaced faith in the potency of postmodern soft power as foreign policy plan A through Z.

Ukraine’s rapid transformation from homo Sovieticus–ruled kleptocracy to inspiring popular revolution to the latest victim of Russian imperialism has been astonishing. In the span of mere weeks, Ukraine’s political cleavages have been magnified as the faultline of a tense geopolitical contest between the Euro-Atlantic community and a revanchist, increasingly militant Russia. In the Western scramble to come to terms with the new threat landscape—let alone formulating an effective, unified response—Crimea has almost certainly already been lost. Meanwhile, Russia seems poised to expand its writ into other areas of eastern Ukraine just as it aggressively probes Euro-Atlantic readiness in the Baltic, Turkey, and the Caucasus. In Washington, defense and administration officials appear resigned—if only unofficially—to Russian control over Crimea (if not eastern Ukraine) and are digging in for the long haul.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC - Soft Regulation Fails

Soft Regs Fail

Kavanagh 19 [Camino Kavanagh has a PhD in information technology and currently works as a nonresident scholar at the Carnegie Endowment for International Peace, where her research focuses on international security, governance, and emerging technologies, 8-28-2019, “New Tech, New Threats, and New Governance Challenges: An Opportunity to Craft Smarter Responses?”, Carnegie Endowment for International Peace, , accessed 6-28-2022]

Such projects demonstrate the need to first develop safer versions of this powerful technology and raise important issues related to standards and regulation. The consequences of using such technologies are not contained within national borders, and these effects will likely require some form of transnational mechanism that considers the views of all stakeholders. This calls for a more harmonized approach to biotech policy, especially since rules and practices of gene editing vary significantly from country to country. Meanwhile, all stakeholders, including those funding and supporting research, need to ensure adherence to existing guidance such as the World Health Organization’s (WHO) 2014 set of guidelines for testing genetically modified mosquitoes.132 According to some experts, this push to shore up standards might require the establishment of some form of accountability mechanism that can, at a minimum, oversee adherence to this guidance and identify possible obstacles to implementation.133

Another ecological risk is the potential for biological attacks against food and water resources, which, as discussed further below, would cause economic damage as well as a “loss of confidence in the food supply, and possible loss of life.”134 For example, a recent study determined that scientists’ deepening understanding of the genomes of plants and animals will make it theoretically possible to target vulnerabilities with greater precision or to create new varieties of organisms with potentially harmful properties. The authors posit that “if plant or animal pathogens [a]re engineered to spread widely in the world in crops or herds, respectively, the result could be widespread and lasting food shortages.”135

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC - Squo Solves

Squo solves risky research

Kaiser 22 [ Jocelyn Kaiser, staff writer for Science magazine, 3-1-2022, “Spurred by Pandemic, U.S. government will revisit federal policies on risky virus research”, Science, , accessed 6-28-2022]

In the wake of the coronavirus pandemic, the U.S. government is revisiting its oversight of experiments that involve modifying pathogens in ways that might make them more harmful to people. Yesterday, White House officials and the National Institutes of Health (NIH) asked an expert advisory board to undertake a swift, broad review of the agency’s policies that aim to make sure federally funded studies of viruses and other microbes that could cause a pandemic are undertaken safely, and to bar funding for experiments deemed too risky.

The review—to be conducted over 10 months by the National Science Advisory Board for Biosecurity (NSABB)—could include consideration of whether controversial coronavirus experiments funded by the United States in China should have received stricter scrutiny. The panel might also explore whether the United States should fund any such pathogen research conducted abroad, where NIH may have less ability to enforce its rules.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC - No bioterror

Biological terror wont happen — assumes CRISPR

Revill 17 [Dr. James Revill, Research Fellow with the Harvard Sussex Program at SPRU, “Past as Prologue? The Risk of Adoption of Chemical and Biological Weapons by Non-State Actors in the EU”, European Journal of Risk Regulation, 2017, , accessed 6-28-2022]

In most cases terrorist groups appear to have largely opted for the simplest pathway towards the achievement of their goals and the weapons used tend to be vernacular, functional devices drawing on local and readily-available materials, rather than sophisticated, “baroque” technologies. This is certainly the case with IEDs, the history of which is characterised largely by incremental innovations – although nevertheless frequently effective ones – with many means of delivery recycled from the past.44 Complexity can therefore be seen as important in the adoption of technology by terrorists generally, but is perhaps particularly acute in the case of CBW technology. Some CBW can be relatively simple: “chlorine-augmented, vehicle-borne IEDs,” as employed by Al-Qaeda in Iraq (AQI) from 2006 to 2007 are not sophisticated weapons.45 Attacks on chemical production facilities, an apparent tactic of Serbian forces in the early to mid-1990s,46 employed relatively simple technologies – specifically explosives – with toxicity a secondary by-product. Direct contamination of food,47 drink48 or healthcare products49 does not require particularly sophisticated technology for the purposes of delivery – although may require some considerable skill to culture and scale-up a biological agent – and has been a common approach in European CBW incidents.50 Similarly, the contamination of water systems, something familiar to Europe,51 can also be relatively easily attempted. However, in most cases such methods of dissemination have generated results that are far short of the “mass destruction” that CBW are associated with, although this does not mean such a possibility can be ignored by those working on public health preparedness. Although some relatively simple approaches could cause significant harm, mass casualty attacks still require considerable expertise, something particularly acute in the context of biological weapons.52 The most effective route to weaponising biology is arguably through the process of aerosolising agents, something recognised mid-way through the last century as opening up the theoretical possibility of using biological weapons on a gigantic scale.53 However, realising such theoretical potential is difficult and it took states decades to develop more predictable biological weapons,54 and even then such weapons were acutely vulnerable to environmental factors. 55 For non-state groups such complexity has proven a significant barrier to CBW development. By means of an example, one of the best-resourced biological weapons programs, that of Aum Shinrikyo, failed variously because the group acquired the wrong strain, contaminated fermenters and were faced with insurmountable production and dissemination difficulties.56 There are of course exceptions, such as the 2001 anthrax Letter Attacks in the US. However, if one accepts the conclusions of the FBI that this sophisticated attack with aerosolised anthrax in the US postal system was perpetrated by a US biodefence researcher, Dr Bruce Ivins,57 it is an exception that proves the rule.

2022 Michigan Negative
Disad things › AT: Biotech Advantages › 1NC - No bioterror

Bioterror impact is false and overblown

Lentzos 17[ Filippa Lentzos, Senior research fellow jointly appointed in the Departments of War Studies and of Global Health and Social Medicine at King’s College London, 7-3-2017, "Ignore Bill Gates: Where bioweapons focus really belongs;", Bulletin of the Atomic Scientists, , accessed 6-28-2022]

I disagree. At a stretch, terrorists taking advantage of advances in biology might be able to create a viable pathogen. That does not mean they could create a sophisticated biological weapon, and certainly not a weapon that could kill 30 million people. Terrorists in any event tend to be conservative. They use readily available weapons that have a proven track record—not unconventional weapons that are more difficult to develop and deploy. Available evidence shows that few terrorists have ever even contemplated using biological agents, and the extremely small number of bioterrorism incidents in the historical record shows that biological agents are difficult to use as weapons. The skills required to undertake even the most basic of bioterrorism attacks are more demanding than often assumed. These technical barriers are likely to persist in the near- and medium-term future.

Gates does a disservice to the global health security community when he draws media and policy attention to amateurs such as terrorists. Where biological weapons are concerned, the focus should remain on national militaries and state-sponsored groups. These are the entities that might have the capability, now or in the near future, to develop dangerous biological weapons. The real threat is that sophisticated biological weapons will be used by state actors—or by financially, scientifically, and militarily well-resourced groups sponsored by states.

2022 Michigan Negative
Disad things › DA - Hungary › 2NC – Human Rights

COVID decimated rule of law and democratic institutions – democratic backsliding amplifies human rights abuses

HRW 21 – Human Rights Watch, International NGO that exposes and studies human rights violations and petitions for governmental action [HRW. “World Report 2021: Hungary.” Human Rights Watch. 2021. https://www.hrw.org/world-report/2021/country-chapters/hungary]

The government used the Covid-19 pandemic as a pretext to continue its attacks on rule of law and democratic institutions. The government declared a state of emergency in March, seizing unlimited power to rule by decree without parliamentary and judicial review. Before the state of emergency was revoked in mid-June, the government had issued hundreds of decrees, including on issues unrelated to public health. The government made access to asylum close to impossible, interfered with independent media and academia, launched an assault on members of the lesbian, gay, bisexual, and transgender (LGBT) community, and undermined women’s rights. Hungary’s Roma minority continue to face widespread and systemic discrimination.

In its Rule of Law report released in October, the European Union Commission raised concerns about the lack of independence of the judiciary, intimidation of independent media, and the impact of the weakening of independent institutions and pressures on civil society on democratic checks and balances.

2022 Michigan Negative
Disad things › DA - Turkey › 2NC – Human Rights

Torture, police brutality, and poor prison conditions undermine human rights

HRW 21 – Human Rights Watch, International NGO that exposes and studies human rights violations and petitions for governmental action [HRW. “World Report 2021: Turkey.” Human Rights Watch. 2021. ]

Torture and Ill-Treatment in Custody, Enforced Disappearances

A rise in allegations of torture, ill-treatment, and cruel and inhuman or degrading treatment in police and military custody and prison over the past four years has set back Turkey’s earlier progress in this area. Those targeted include people accused of political and common crimes. Prosecutors do not conduct meaningful investigations into such allegations and there is a pervasive culture of impunity for members of the security forces and public officials implicated.

2022 Michigan Negative
Disad things › DA - Turkey › 2NC – Human Rights

Turkey is horrible for human rights – lack of judicial independence and authoritarian rule greenlight violence is Syria, Kurds

HRW 21 – Human Rights Watch, International NGO that exposes and studies human rights violations and petitions for governmental action [HRW. “World Report 2021: Turkey.” Human Rights Watch. 2021. ]

The assault on human rights and the rule of law presided over by Turkey’s President Recep Tayyip Erdoğan continued during the Covid-19 pandemic. The president’s Justice and Development Party (AKP) and an allied far-right party enjoy a parliamentary majority enabling them to consolidate authoritarian rule by passing rushed legislation that contravenes international human rights obligations. Opposition parties remain sidelined under Turkey’s presidential system and the government has reshaped public and state institutions to remove checks on power and to ensure benefits for its own supporters. The political opposition nevertheless controls the municipalities of Istanbul and Ankara.

Executive interference in the judiciary and in prosecutorial decisions are entrenched problems, reflected in the authorities’ systematic practice of detaining, prosecuting, and convicting on bogus and overbroad terrorism and other charges, individuals the Erdoğan government regards as critics or political opponents. Among those targeted are journalists, opposition politicians, and activists—in particular members of the pro-Kurdish Peoples’ Democratic Party (HDP). The largest targeted group consists of those alleged to have links with the movement headed by US-based Sunni cleric Fethullah Gülen which Turkey deems a terrorist organization and calls FETÖ and holds responsible for the July 2016 coup attempt.

2022 Michigan Negative
Disad things › DA/Turn - China Biotech Good › 1NC – No Tech Race

China and American biotech can develop cooperatively.

Moore and Coplin 22 (Scott Moore and Abigail Coplin, “Closing the U.S. to Chinese Biotech Would Do Far More Harm Than Good”, China File, April 8th 2022, , WC-NAS)

China is fast becoming a biotechnology powerhouse and a perceived threat to the longstanding dominance of the United States in the sector. In Washington, these developments have been greeted in much the same way as China’s growing prowess in artificial intelligence and other emerging technologies: with panic and punitive measures. Last May, Florida Republican Senator Marco Rubio introduced the , which would, among other actions, ban the National Institutes of Health from funding China-affiliated entities. In September, Arkansas Republican Senator Tom Cotton and Wisconsin Representative Mike Gallagher  for “” Chinese biotechnology companies over concerns they may be attempting to gather biomedical information on U.S. citizens for nefarious purposes. Just a few months later, the U.S. government  12 Chinese life sciences research institutes and 22 private firms on security grounds.

There is a big problem, however, with these largely reactive, security-focused responses. Biotechnology is an intrinsically transnational and rapidly evolving sector that holds just as much promise for mutually beneficial collaboration and cooperation as for competition and contention. These distinctive characteristics of biotechnology mean that Washington’s security-driven approach to China and biotechnology risks harming U.S. competitiveness in the sector instead of enhancing it, while also limiting America’s ability to share in the development of mutually-beneficial technologies and work with Beijing to address the shared challenges posed by rapid developments in fields like gene editing. U.S. policy and strategy on China and biotechnology must strike a better balance between addressing legitimate concerns while maintaining the openness and innovation that underpin America’s competitive advantage in emerging technology.

2022 Michigan Negative
Disad things › DA/Turn - China Biotech Good › --xt No China Model

China will not model US policy

Ho 21 [ Benjamin Ho, assistant professor in the China Programme at the Institute of Defense and Strategic Studies at the S. Rajaratnam School of International Studies, 8-25-2021,”Why China Will Not Cooperate with the West: The Pandemic Made Things Worse”, The National Interest, , accessed 6-28-2022]

Seen this way, it is not surprising that China fundamentally does not trust the United States. Not only does Beijing see Washington’s objective as wanting to keep it down and preserving its international primacy, it also views the current Biden administration—and its emphasis on democracy promotion—as an existential threat to its political worldview. Indeed, Western criticisms of Beijing on Xinjiang, Hong Kong, and Tibet all feed into the CCP’s central narrative: the United States and the West want to challenge the Party’s grip on power and to remake China in the image of the West. Such a siege mentality means that Beijing is unlikely to find any common ground with the United States insofar as key strategic interests are concerned. Consequently, the CCP also views statements made by the United States and the West as trying to drive a wedge between itself and its citizens—which would effectively destroy its sacralized image and its paramount leader that has been so carefully and painstakingly built up over the years. Indeed, Chinese political observers—in their recount of the fall of the Soviet Union—often point not to Mikhail Gorbachev’s glasnost and perestroika, rather they attribute it to Nikita Khrushchev’s denouncement of Stalin as the start of the Soviet long decline. Unity is paramount to preserving the sacralized image of the party, and the CCP will go all out to defend this.

The events of the coronavirus pandemic have further exacerbated the tensions between China and the United States, not least because of the sky-high implications that are at stake. Given that China wants to portray itself as a responsible nation, one that is better than the West, it has spared no effort to promote its vaccines worldwide, particularly in countries who for various reasons are unable to procure the Pfizer or Moderna vaccines. While most foreign ministers would prefer to defer knowledge of vaccine science to health experts, in China, the foreign ministry has been on the forefront of vaccine promotion. The implications are obvious: Beijing sees vaccine diplomacy as a crucial means with which to convince other countries of its goodwill and friendship. Paired together with its Wolf Warrior diplomacy, in which China seeks to rebut what it sees as unfair allegations by unfriendly nations, Beijing intends to seize the moral high ground to claim that it is superior to the West.

2022 Michigan Negative
Disad things › DA/Turn - China Biotech Good › --AT: US Lead Key

China places strict tech regs and doesn’t model US ones

AIQ 21 (AIQ Editorial, “China’s Big Tech crackdown”, Aviva Investors, July 5th 2021, , WC-NAS)

For many years, Beijing took a hands-off approach to the technology sector, willing to countenance the rapid growth of national champions that provided convenient services to the population at home and commanded respect on the world stage. But now the government has changed tack, and for reasons that differ from those driving recent regulatory moves in the West.

“Regulation of technology companies is tightening everywhere – it’s a global trend. In practice, though, Chinese tech firms were already under much more state influence than their counterparts in the US or Europe. What we are seeing is more of a shift in emphasis from the authorities,” says Alistair Way, head of equities at Aviva Investors.